john eng glp-1 🦎 One of the world's most talked-about medicines owes a lot to… a venomous lizard. Researchers studying the saliva of the Gila monster discovered a molecule similar to GLP-1. That discovery helped History of glucagon-like peptide-1 receptor

Do D et al

[Leggi larticolo] Semaglutide e MASH: la prima approvazione di un GLP-1 RA in epatologia (in pubblicazione) Lo studio ESSENCE (NEJM 2025) ha portato allapprovazione FDA accelerata di Wegovy per la steatoepatite metabolica con fibrosi F2-F3 (agosto 2025)

About 1 in 8 US adults aged 18 years or older (12% of US adults!) report having used a glucagon-like peptide 1 (GLP-1) agonist medication , according to results from a KFF (formerly Kaiser Family Foundation) poll often for weight loss rather than for diabetes

GLP-1 receptor agonists as a drug class have substantial clinical trial evidence supporting significant weight loss outcomes, with peer-reviewed research demonstrating statistically meaningful reductions in body weight in large randomized controlled trials

American Thyroid Association